These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1777898)

  • 1. Antimouse antibody response after OKT3 administration for steroid resistant rejection.
    Kaiser BA; Palmer JA; Dunn SP; Mochon MA; Bartosh SM; Schulman SL; Polinsky MS; Baluarte HJ
    Child Nephrol Urol; 1991; 11(4):190-2. PubMed ID: 1777898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitization to OKT3 monoclonal antibody in heart transplantation: correlation with early allograft loss.
    O'Connell JB; Renlund DG; Hammond EH; Wittwer CT; Yowell RL; DeWitt CW; Jones KW; Gay WA; Menlove RL; Bristow MR
    J Heart Lung Transplant; 1991; 10(2):217-21; discussion 221-2. PubMed ID: 1903303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reuse of OKT3 after previous rejection or induction therapy in cadaveric renal transplantation.
    Shield CF; Hughes JD
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):35-8. PubMed ID: 2510509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients.
    Toyoda M; Galfayan K; Wachs K; Czer L; Jordan SC
    Clin Transplant; 1995 Dec; 9(6):472-80. PubMed ID: 8645891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M; Latter DA; Loertscher R
    Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
    Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
    Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
    [No Abstract]   [Full Text] [Related]  

  • 9. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation.
    Shennib H; Massard G; Reynaud M; Noirclerc M
    J Heart Lung Transplant; 1994; 13(3):514-9. PubMed ID: 8061029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OKT3 for the treatment of steroid-resistant acute renal allograft rejection.
    Jogose JT; Bailey RR; Lynn KL; Robson RA; Wells JE
    Nephron; 1997; 77(3):298-303. PubMed ID: 9375823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OKT3 antibody response study: comparative testing of human antimouse antibody.
    Kimball JA; Norman DJ; Shield CF; Schroeder TJ; Lisi P; Garovoy M; O'Connell JB; Stuart F; McDiarmid SV; Wall W
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):74-6. PubMed ID: 8465432
    [No Abstract]   [Full Text] [Related]  

  • 14. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?
    Wagner FM; Reichenspurner H; Uberfuhr P; Kur F; Kaulbach HG; Meiser BM; Ziegler U; Reichart B
    J Heart Lung Transplant; 1994; 13(3):438-42; discussion 442-3. PubMed ID: 8061020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
    Shield CF
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
    [No Abstract]   [Full Text] [Related]  

  • 16. [OKT3 treatment of refractory renal allograft rejection].
    Xu J; Ma J; Bai X
    Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation.
    Pascher A; Radke C; Dignass A; Schulz RJ; Veltzke-Schlieker W; Adler A; Sauer IM; Platz K; Klupp J; Volk HD; Neuhaus P; Mueller AR
    Transplantation; 2003 Aug; 76(3):615-8. PubMed ID: 12923454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
    Macris MP; Frazier OH; Lammermeier D; Radovancevic B; Duncan JM
    J Heart Transplant; 1989; 8(4):281-7. PubMed ID: 2504894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined high and low dosing of OKT3 for treatment of rejection episodes in renal transplants.
    Schweizer RT; Bartus S; Hull D; Perdrizet G; Roper L
    Transplant Proc; 1994 Dec; 26(6):3141. PubMed ID: 7998094
    [No Abstract]   [Full Text] [Related]  

  • 20. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.